Not medical advice. Talk to your provider before using any peptide. Full disclaimer
NA-Semax Amidate
Beginner tier: 100 mcg, daily · 2w on / 2w off · community consensus
Also known as: NA-Semax, N-Acetyl Semax Amidate, NASA (informal community abbreviation)
A single intranasal spray triggers a 3-fold increase in BDNF mRNA in the hippocampus, based on rodent data from the parent compound Semax [1]. NA-Semax Amidate (N-Acetyl Semax Amidate) is the stabilized, higher-potency version of Russia's approved nootropic peptide. No human clinical trials exist for this specific modification. The cognitive benefits persist 1 to 3 weeks after you stop dosing, which is why cycles run just 10 to 20 days. Nootropic users who want sharper focus, better verbal fluency, and sustained BDNF elevation without daily long-term dosing tend to reach for this one.
What Is NA-Semax Amidate?
NA-Semax Amidate (N-Acetyl Semax Amidate, CAS pending) is a stabilized derivative of Semax with an estimated 3 to 5 times greater potency per microgram. Dolotov and colleagues showed the parent compound Semax produced a three-fold BDNF mRNA increase from a single dose in rat hippocampus [1], and NA-Semax Amidate pushes the pharmacokinetics further.
The modification is straightforward. An N-terminal acetyl group blocks aminopeptidase degradation. A C-terminal amide cap blocks carboxypeptidase attack. The core sequence, ACTH(4-10) extended with Pro-Gly-Pro, stays identical to the parent compound approved in Russia for cognitive and neuroprotective indications. The result is a peptide that resists enzymatic breakdown in neural tissue longer than standard Semax, translating to an estimated 3 to 5 times greater potency per microgram.
In practice, experienced nootropic users dose 100 to 300 mcg intranasally each morning for 10 to 20 day cycles. The peptide activates melanocortin receptors (MC3R, MC4R) and upregulates both BDNF and NGF in the basal forebrain. It also modulates serotonergic, dopaminergic, and enkephalin signaling pathways. Community reports across roughly 50 to 100 Reddit threads describe improved verbal fluency, working memory, and stress resilience within the first few days, with peak cognitive effects by days 7 to 10.
The honest picture: zero human clinical trials exist for NA-Semax Amidate specifically. Every mechanistic citation traces back to the parent compound. PubMed returns about 12 results for "N-acetyl Semax" compared to roughly 150 for standard Semax. The potency multiplier is a pharmacokinetic inference, not a validated human comparison. Community experience across users who dose correctly has been consistently positive, but this is a preclinical compound with community-derived dosing.
How NA-Semax Amidate Works
NA-Semax Amidate is a synthetic analog of ACTH(4-10) extended with a Pro-Gly-Pro tripeptide tail. It activates melanocortin receptors MC3R and MC4R in the brain without triggering adrenal cortisol release, which separates it from full-length ACTH.
The primary neurotrophic action comes through BDNF upregulation. Dolotov and colleagues showed that a single application of Semax at 50 mcg/kg produced a 1.4-fold increase in BDNF protein and a 3-fold increase in exon III BDNF mRNA in the hippocampus [1]. TrkB receptor phosphorylation increased 1.6-fold in the same study. A separate group confirmed that Semax raises NGF levels in the basal forebrain [2].
Beyond neurotrophins, the peptide modulates serotonergic, dopaminergic, and enkephalin (opioid) signaling systems. This multi-pathway engagement likely explains the combined cognitive and mood effects that community users consistently describe.
The N-acetyl and amide modifications don't change receptor binding. They increase resistance to aminopeptidase and carboxypeptidase degradation. Magrì and colleagues studied N-terminal acetylation of Semax directly [3]; it is one of the few peer-reviewed studies of the modification. The practical effect is extended duration of activity in neural tissue compared to the parent compound.
NA-Semax Amidate Benefits
- NA-Semax Amidate benefits center on neurotrophic upregulation and cognitive performance during short intranasal cycles.
- Estimated 3 to 5 times more potent than standard Semax per microgram, meaning lower doses and shorter cycles can achieve equivalent or greater neurotrophic stimulation.
- BDNF and NGF upregulation supports learning, memory consolidation, and neuroplasticity. Parent compound data shows 1.4-fold BDNF protein increase and 3-fold BDNF mRNA increase in rat hippocampus at 50 mcg/kg [1].
- Neuroprotective effects confirmed in cerebral ischemia-reperfusion models. Genome-wide transcriptional analysis of Semax in focal ischemia identified changes in immune and vascular gene expression [4].
- Mood stabilization and stress resilience through serotonin and dopamine pathway modulation. Community users report reduced anxiety at appropriate doses, improved motivation, and emotional steadiness during the cycle window.
- Cognitive benefits persist 1 to 3 weeks after the cycle ends. BDNF and NGF protein levels remain raised post-cessation in rodent Semax models, making the off-period a productive continuation rather than a gap.
- Users report 6 to 12 hours of cognitive effect per dose, compared to 2 to 4 hours with standard Semax. Onset is rapid at 5 to 15 minutes intranasal.
NA-Semax Amidate: Science vs Community Consensus
No human clinical trials exist for NA-Semax Amidate specifically.
Read the evidence (key study, limitations)
All mechanistic evidence derives from the parent compound Semax: approved in Russia for cognitive/neuroprotective indications and studied in human ischemia settings. The N-acetyl + C-terminal amide modifications are pharmacokinetically rational (protease resistance, extended intraneural duration) but unstudied in humans as a distinct compound. The 3–5× potency multiplier quoted here is a pharmacokinetic inference, not a formally validated human potency comparison.
Dolotov et al. 2006 (PMID 16996037): Semax produces 3-fold BDNF mRNA increase and 1.6-fold TrkB phosphorylation in rat hippocampus at 50 mcg/kg (parent compound, not NA-Semax Amidate). For the acetylation itself, Magrì et al. 2016 (PMID 27586814) found that N-terminal acetylation changes how Semax binds copper. In neuroblastoma cells, the acetylated form did not protect against copper toxicity. It is one of the few peer-reviewed studies of the modification.
No human RCTs for NA-Semax Amidate. PubMed count ~12 for "N-acetyl Semax" vs ~150 for parent Semax: extreme evidence gap for the modified form. Four of its five references are for parent Semax; the fifth studies N-acetyl Semax, and none tests the amidate form. Potency multiplier (3–5×) is a community estimate from pharmacokinetic reasoning, not a controlled human comparison. Its research status is preclinical.
Positive but niche.
Read the reports (what users report 5, common issues 4)
Experienced nootropic users consistently report clear cognitive enhancement and mood stabilization at appropriate doses. Community consensus: superior duration and smoother profile than standard Semax at corrected dose. The #1 failure mode is treating it as equivalent-dose to parent Semax due to the 3–5× potency difference.
- Longer duration of cognitive effect vs parent Semax (community reports 6–12h vs 2–4h)
- Rapid onset 15–30 min intranasal; noticeable verbal fluency and working memory improvement
- Mood stabilization and anxiety reduction at appropriate doses (paradoxically: high doses cause anxiety)
- Cognitive benefits persist 1–3 weeks post-cycle due to sustained BDNF/NGF elevation
- Smoother stimulation profile than standard Semax at equivalent starting doses
- Potency mismatch vs standard Semax: #1 user error; treating it as equivalent dose causes overstimulation and anxiety
- Sleep disruption with late-day dosing (afternoon or evening use)
- Higher cost per mg vs parent Semax; limited availability compared to Semax
- Hair thinning reported at high doses by some users: rare, reportedly reversible, no clinical documentation
Community dosing, cycling rationale (10–20 day cycles), and route preference (intranasal) align with the Russian Semax clinical protocol tradition. Reported mechanism (BDNF upregulation, cognitive enhancement, neuroprotection) matches the validated parent compound mechanism. Divergent on the potency multiplier: community consensus of 3–5× is pharmacokinetically reasonable but not formally validated in humans. Science has no direct human data for NA-Semax Amidate; all parent-compound endorsement is inferred across the modification.
NA-Semax Amidate Dosage Guide
Start at 100 mcg intranasal, period. The potency mismatch with standard Semax is the number one user error. If you were running Semax at 300 mcg, your starting dose here is 100 mcg.
Reconstitution math for intranasal: 10 mg vial plus 10 mL bacteriostatic water gives you 1 mg/mL (1000 mcg/mL). A standard nasal atomizer delivers about 0.1 mL per actuation, so each spray is 100 mcg. Three sprays gets you 300 mcg. Split across nostrils, wait 5 minutes between sides.
For subcutaneous (less common): 10 mg vial plus 4 mL bacteriostatic water gives you 2.5 mg/mL. On a U-100 insulin syringe, 100 mcg is 4 IU, 300 mcg is 12 IU, 600 mcg is 24 IU.
Dose before 10 AM. Nothing after 1 PM. The dopaminergic tail will wreck your sleep if you dose late. Refrigerate the reconstituted spray at 2 to 8 degrees C and toss it after 30 days. Lyophilized vials survive shipping better than pre-mixed sprays.
Cycling Protocol
Standard protocol is 10-20 days on, 10-20 days off. Cognitive benefits often persist during the off period due to sustained BDNF elevation. Some users run 30-day cycles with longer breaks.
Primary rationale from the original Russian Semax clinical protocols: cycling prevents melanocortin receptor (MC3R/MC4R) desensitization with sustained agonist exposure. Secondary: BDNF and NGF upregulation reaches a plateau within 10–20 days, making continued dosing yield diminishing returns while the neurotrophic benefits persist post-cessation: the off-period is a productive continuation of the effect, not a gap. Community users also cite a "fresh response" upon returning after the off-period as empirical evidence of receptor resensitization.
- Diminishing cognitive response despite continued dosing at the same dose (BDNF/NGF plateau)
- Increasing anxiety or irritability over consecutive days suggesting cumulative receptor activation
- No additional subjective benefit perceived after day 10 of cycle at a stable dose
Or use the universal Peptide Calculator for any peptide.
NA-Semax Amidate Protocols by Goal
Expected: Improved focus, verbal fluency, and working memory within days 1–3. Mood stabilization by end of week 1. Cognitive benefits typically persist 1–2 weeks post-cycle.
Monitor: Track anxiety and sleep quality daily. Reduce or skip dose if waking earlier than baseline or noticing irritability building over consecutive days.
How to Use NA-Semax Amidate
- 1Reconstitute the vial
Add 10 mL of bacteriostatic water to a 10 mg NA-Semax Amidate vial. This gives you 1 mg/mL (1000 mcg/mL). Swirl gently, do not shake. Let the powder dissolve fully.
- 2Load the nasal spray device
Transfer the reconstituted solution into a calibrated nasal atomizer (0.1 mL per actuation). Each spray delivers 100 mcg.
- 3Clear your nasal passages
A gentle saline rinse before dosing reduces irritation and improves absorption.
- 4Administer the dose
Tilt your head slightly forward. Insert the spray tip into one nostril while closing the other. Press once and inhale gently. If your target dose is 200 mcg or higher, wait 5 minutes, then spray the other nostril.
- 5Time it right
Dose in the morning, ideally before 10 AM. Do not dose after 1 PM. The stimulatory effects last 6 to 12 hours.
- 6Store properly
Refrigerate the reconstituted spray at 2 to 8 degrees C. Discard after 30 days. Keep lyophilized (unreconstituted) vials at room temperature for up to 30 days, refrigerated for up to 24 months.
For subcutaneous injection (alternative route): reconstitute 10 mg in 4 mL bacteriostatic water for 2.5 mg/mL. Use a 29 to 31 gauge insulin syringe. 100 mcg equals 4 IU on a U-100 syringe. Inject into abdominal subcutaneous fat, rotate sites. Expect onset in 30 to 45 minutes versus 5 to 15 minutes intranasal.
Alternative Routes
Reference standard for all community dosing. Estimated intranasal bioavailability to CNS: 30–50% (improved over standard Semax due to amide cap; some sources cite up to 60%). Onset 5–15 min.
Reconstitute 10 mg vial in 10 mL BAC water = 1 mg/mL. Standard nasal atomizer at ~0.1 mL/actuation = 100 mcg per spray. Store reconstituted spray refrigerated at 2–8°C; discard after 30 days.
Same mcg dosing as intranasal (no established dose adjustment). Onset ~30–45 min vs 5–15 min intranasal. Lower estimated CNS bioavailability per dose but more precise volumetric administration.
Reconstitute 10 mg vial in 4 mL BAC water = 2.5 mg/mL (2500 mcg/mL). Inject into abdominal subcutaneous fat; rotate sites. U-100 insulin syringe units: 100 mcg = 4 IU, 300 mcg = 12 IU, 600 mcg = 24 IU.
NA-Semax Amidate Stacking Protocols
Works With
Complementary mechanism: Selank is GABAergic and anxiolytic; counters the stimulatory/dopaminergic profile of NA-Semax Amidate. Community describes the combination as "cognitive clarity + calm." The most frequently cited NA-Semax Amidate stack. Both are intranasal, allowing co-administration.
NA-Semax Amidate 100–300 mcg intranasal AM + Selank 250–500 mcg intranasal AM or midday. Can co-administer or stagger by 30 min.
Dopaminergic baseline support: Bromantane raises dopamine synthesis via tyrosine hydroxylase upregulation. Community stacks for enhanced motivational drive alongside BDNF/cognitive effects of NA-Semax Amidate. Monitor for additive stimulation.
NA-Semax Amidate 100–300 mcg intranasal AM + Bromantane 50–100 mg oral AM. Avoid if prone to anxiety.
Complementary neurotrophic axes: Dihexa targets HGF/c-Met pathway for synaptogenesis; NA-Semax Amidate targets BDNF/ACTH pathway. Community stacks for broader neurotrophic coverage. Both are research-only with no human safety data for the combination.
Dihexa 5–10 mg/day oral + NA-Semax Amidate 100–300 mcg intranasal AM. Run concurrent cycles (14–20 days on, 14–20 days off).
Cholinergic support: community adds Alpha-GPC to support acetylcholine availability when BDNF-driven synaptic demand increases and to prevent headache patterns sometimes associated with increased synaptic activity. No pharmacological conflict with NA-Semax Amidate.
Alpha-GPC 300 mg oral AM, taken 30 min before intranasal NA-Semax Amidate.
Avoid
NA-Semax Amidate upregulates serotonergic and dopaminergic signaling. Combining with MAOIs risks excessive monoamine accumulation and potential serotonin syndrome. Also listed under its drug interactions.
Do not combineAdditive CNS stimulation from overlapping dopaminergic upregulation. Substantially increases risk of anxiety, agitation, cardiovascular stress, and insomnia. Also listed under its drug interactions.
Parent compound Semax influences vascular gene expression (PMID 24661604). Precautionary: no direct interaction data for NA-Semax Amidate specifically.
Estimated Cost
Pricing updated 2026-04-09
NA-Semax Amidate Side Effects
Overstimulation is the most reported problem with NA-Semax Amidate, and it is almost always self-inflicted. The compound is 3 to 5 times more potent per microgram than standard Semax. Users who transfer their parent compound dose directly (e.g. 300 mcg Semax mapped straight to 300 mcg NA-Semax Amidate) experience anxiety, agitation, and irritability. This is the number one failure mode cited across community reports.
The anxiety response deserves emphasis. NA-Semax Amidate upregulates dopaminergic and serotonergic signaling. At higher doses, that stimulation tips from productive focus into agitation. Users with a history of anxiety disorders face increased risk; this compound is listed as contraindicated for severe anxiety disorders for exactly this reason. If anxiety appears, drop to 100 mcg and dose before 10 AM. Resolution typically happens within 1 to 2 days at the reduced dose.
Sleep disruption ranks second among community complaints. The dopaminergic upregulation has a 6 to 12 hour activity tail. Dosing after 1 PM is the primary cause. Shifting the dose earlier in the morning typically resolves sleep disruption within 2 to 3 days.
Hair thinning has been reported at sustained doses above 300 mcg per day over 30 or more days. The speculated mechanism involves melanocortin receptor (MC4R) activity. No clinical documentation exists for this effect; community reports indicate it reverses after cessation. The reports are rare.
Nasal irritation can occur with intranasal use. Reconstituting above 2.5 mg/mL concentration increases irritation risk. Using a saline rinse before dosing helps. If irritation persists, subcutaneous injection is an alternative route.
The human safety dataset is extremely limited. All published data comes from the parent compound Semax, not the amidate modification. PubMed returns about 12 results for the modified form. The researchStatus is correctly tagged as preclinical. No formal adverse event reporting exists.
Contraindications include pregnancy, breastfeeding, known hypersensitivity to Semax or ACTH-derived peptides, active bleeding disorders, and history of severe anxiety disorders. If combining with MAO inhibitors, the risk of excessive monoamine accumulation and serotonin syndrome is real; that combination should be avoided. Stimulant medications (amphetamines, methylphenidate) carry additive CNS stimulation risk. Anticoagulant users should monitor closely given Semax's documented influence on vascular gene expression [4].
Stop use and consult a physician if new anxiety disorder symptoms appear, if insomnia persists despite timing adjustments, or if blood pressure exceeds 140/90 mmHg.
Common Issues & Solutions
Anxiety or overstimulation: Almost always a dose mismatch: this compound is 3–5× more potent than standard Semax. Users who transfer their Semax dose directly will overdose. Reduce to 100 mcg, dose before 10 AM, avoid all other stimulants. Resolution expected within 1–2 days at reduced dose.
Sleep disruption: Late dosing is the primary cause. The dopaminergic upregulation has a 6–12h activity tail. All doses must be taken before 1 PM. Shifting dose timing earlier typically resolves sleep disruption within 2–3 days.
No noticeable effect: Verify reconstitution: 10 mg vial in 10 mL BAC water = 1000 mcg/mL = 100 mcg per 0.10 mL actuation. Confirm the nasal spray device is delivering the correct volume. If using SubQ, consider switching to intranasal for superior direct CNS access. Allow 5–7 full days before evaluating efficacy.
Hair thinning (rare): Community-reported at sustained high doses (>300 mcg/day over 30+ days). Speculated mechanism: melanocortin receptor (MC4R) activity. No clinical documentation; appears reversible after cessation. Reduce dose or discontinue if observed.
Nasal irritation: Dilute the spray solution: standard is 1 mg/mL (10 mg in 10 mL); going above 2.5 mg/mL increases irritation risk. Saline rinse before dosing helps. If persistent, switch to SubQ route.
Ask AI about this page
Ask AI for a second opinion on NA-Semax Amidate dosing and side effects
Contraindications
- Pregnancy or planning to become pregnant
- Breastfeeding
- Known hypersensitivity to Semax or ACTH-derived peptides
- Active bleeding disorders (peptide may influence immune/vascular gene expression)
- History of severe anxiety disorders (may worsen at higher doses)
Drug Interactions
- MAO inhibitors: potential for excessive serotonergic/dopaminergic stimulation
- Stimulant medications (amphetamines, methylphenidate): additive CNS stimulation, use caution
- Anticoagulants: Semax influences vascular gene expression; monitor if combining
- Thyroid hormones: melanocortin pathway interactions; monitor thyroid function
- Anticoagulants (warfarin, heparin)
Product Quality
Research-only compound with no FDA manufacturing oversight. Smaller market volume vs mainstream peptides means fewer products on the market and less competitive quality pressure. Intranasal formulations require sterility and endotoxin standards that not all research-grade products meet. No large-scale independent purity testing data exists for this compound.
- Quality benchmark: a batch-specific HPLC certificate of analysis showing ≥99% purity and confirmed molecular weight (MW 855.0 for NA-Semax Amidate).
- For intranasal use, verify endotoxin testing on the COA: nasal mucosa is immunologically sensitive; endotoxin exposure via intranasal route is a documented concern.
- Lyophilized powder vials (self-reconstitute) are more stable during shipping than pre-reconstituted spray bottles.
- Reconstitute intranasal solutions with bacteriostatic saline or BAC water only: plain distilled water lacks preservative and degrades faster.
- Refrigerate reconstituted spray at 2–8°C; use within 30 days. Do not freeze the reconstituted spray solution.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Blood pressure | Baseline before first dose; mid-cycle (day 7); any time symptoms arise | <130/80 mmHg at rest; hold dose and evaluate if >140/90 mmHg |
| Anxiety and mood self-assessment | Daily during cycle | Any new or worsening anxiety disorder symptoms, persistent irritability, or insomnia → reduce dose or discontinue |
| Sleep quality log | Nightly throughout cycle | Sleep onset within 30 min of personal baseline; no significant early waking |
Melanocortin receptor (MC3R/MC4R) activation may influence vascular tone. Uncontrolled hypertension is a gap in peptides.ts contraindications: flagged in verification JSON; it is listed as a contraindication for parent Semax.
Overstimulation is the primary dose-limiting side effect. Daily tracking prevents normalization of gradually escalating anxiety over multiple dosing days.
Sleep disruption from late dosing is the second most common community complaint. Early detection allows timing adjustment before cumulative sleep debt develops.
NA-Semax Amidate Before and After
Initial effects noticeable within hours of first dose: improved mental clarity, focus, and verbal fluency. Some users report mild stimulation or slight headache as the body adjusts.
Cognitive effects become more consistent. Improved working memory, sustained attention, and motivation. Mood stabilization and reduced anxiety are commonly reported.
Peak benefits during the latter half of the cycle. BDNF elevation reaches steady state. Enhanced learning capacity and stress resilience. End of standard 2-week cycle.
Cognitive benefits often persist for 1-3 weeks after stopping, likely due to sustained BDNF and NGF levels. Effects gradually return to baseline.
What to Expect
Days 1 to 3, acute onset. Most users notice improved mental clarity and verbal fluency within hours of the first intranasal spray. Parent compound data from Dolotov [1] shows BDNF mRNA triples in the rat hippocampus within hours of application. Some mild stimulation is normal. Occasional slight headaches during the first day or two resolve as the body adjusts. Nasal irritation can occur if the solution concentration is too high.
Days 4 to 10, accumulating neurotrophic effects. This is where the cognitive response becomes steady and consistent. Working memory improves, sustained attention sharpens, and motivation picks up. Mood stabilization and stress resilience are commonly described during this window. BDNF protein elevation is sustained and building, based on Semax rodent kinetics. Anxiety or irritability during this phase almost always means the dose was escalated too quickly or timing shifted too late in the day.
Days 11 to 20, peak cycle and decision point. BDNF reaches steady-state based on Russian Semax clinical protocol precedent. Subjective benefits are at their highest. Improved learning capacity and stress resilience are typical. The standard 14-day cycle ends here; some users extend to 20 days. Diminishing marginal improvement can appear, with some users noticing habituation to the focus response past day 14.
Post-cycle, 1 to 3 weeks off. The off-period is productive, not empty. BDNF and NGF protein levels remain raised 1 to 2 weeks post-cessation in rodent models. Community users consistently report that cognitive benefits persist for 1 to 3 weeks after the last dose. The return to baseline is gradual rather than sudden. This persistent post-cycle benefit is the primary community rationale for cycling rather than continuous dosing.
Detailed Timeline: Science vs Community
Intranasal absorption via olfactory neuroepithelium within minutes. Parent Semax shows 3-fold BDNF mRNA increase within hours of application and TrkB phosphorylation by day 1 in rodent hippocampus (PMID 16996037). Acute melanocortin receptor binding expected from first dose.
Most users notice mental clarity, verbal fluency, and improved focus within hours of first dose. Some mild stimulation. Occasional slight headache during first 1–2 days as body adjusts.
BDNF protein elevation sustained and accumulating based on Semax rodent data. TrkB phosphorylation and NGF upregulation in basal forebrain build through this window. Serotonergic and dopaminergic pathway modulation stabilizes.
Cognitive effects become consistent and stable. Improved working memory, sustained attention, motivation, and mood. Stress resilience commonly described. Most users identify this as the most productive phase.
BDNF steady-state based on Russian Semax clinical protocol precedent. 10–20 day cycle length follows original Russian Semax clinical protocol; no direct human data defines the optimal cycle length for NA-Semax Amidate specifically.
Peak subjective benefits. Enhanced learning capacity and stress resilience. Standard 14-day cycle ends here; some users extend to 20–30 days without reported tolerance build.
BDNF and NGF protein levels remain elevated 1–2 weeks post-cessation in rodent Semax models. Structural plasticity changes, if any, may persist beyond drug clearance. N-acetyl/amide modifications extend intraneural residence time vs parent: off-period benefits may exceed those seen with standard Semax.
Cognitive benefits persist for 1–3 weeks post-cycle. Gradual return to baseline rather than a sharp drop-off. The persistent benefit post-cycle is the primary community rationale for the cycling protocol.
Pharmacokinetics
Source: Estimated from Semax PK data; acetylation/amidation extend half-life vs parent compound (~2-3 min IV)
Pharmacokinetics: Active Dose Over Time
t½ = ~5-10 min (intranasal)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is NA-Semax Amidate Legal?
NA-Semax Amidate is classified as a research-only compound. It has no FDA approval, no IND application on record, and no regulatory pathway in progress in any Western jurisdiction. The parent compound Semax holds marketing authorization in Russia for cognitive and neuroprotective indications, but that approval does not extend to the N-acetyl amidated modification.
In the United States, NA-Semax Amidate is sold online as a research chemical, labeled for in-vitro research purposes only. It is not approved for human use by any regulatory body. Compounding pharmacy availability does not apply to this compound.
WADA status is uncertain. The parent compound Semax appears on some national anti-doping watchlists given its melanocortin receptor activity. Athletes subject to drug testing should treat this peptide as a risk.
This content is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any research compound.
Evidence grade: No human studies found (Peptide Evidence Gap, October 2026)
Who Should Consider NA-Semax Amidate
- Individuals seeking cognitive enhancement and improved focus
- Those wanting a more potent and stable alternative to standard Semax
- People interested in neuroprotection and BDNF upregulation
- Users with stress-related cognitive decline or brain fog
Related Peptides
What Changed for NA-Semax Amidate
Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations
References
- [1]Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Influence of the N-terminus acetylation of Semax on copper(II) and zinc(II) coordination and biological properties (Magri et al., J Inorg Biochem 2016) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is NA-Semax Amidate?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 50–100. Community mentions on Reddit: Low (~50–100 threads, much lower than parent Semax).
12 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Low search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.